About the Event
Currently patients with skin diseases such as Atopic Dermatitis (eczema), Rosacea, Alopecia (hair loss), and Vitiligo spend upwards of $13B a year for systemic treatments with varying degrees of efficacy and significant side effects.
CAGE Bio believes that systemic exposure to drugs should be an exception and have developed an Ionic Liquid (IL) platform that allows medication to be applied topically to the area of need, delivering it across the outer layer of the skin. This enables the company to engineer diverse Ionic Liquids with tailor‐made properties for multiple therapeutic areas.
CAGE Bio has a robust pipeline of Ionic Liquid formulations and have begun to enroll patients in Phase 2 trials of the Rosacea program after a very successful Phase 1.
Join our webinar to hear from CAGE Bio CEO, Nitin Joshi as he discusses the opportunity this breakthrough technology presents.